Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
iTeos Therapeutics to Present at the 2017 BIO CEO & Investor Conference
Gosselies, Belgium - February 10, 2017 - iTeos Therapeutics SA, a Belgian privately-held biotechnology company applying its expertise in translational tumor immunology to the development of novel cancer immunotherapies, today announced that Michel Detheux, iTeos' Chief Executive Officer, will present at the 2017 BIO CEO & Investor Conference on Tuesday, February 14 2017 at 10:45 a.m. ET in Park North at The Waldorf Astoria in New York, NY.
If you would like to meet with the iTeos management team, please contact the event organizers or [email protected].
For more information about the 2017 BIO CEO & Investor Conference, please refer to the conference website at: http://ceo.bio.org.
About iTeos Therapeutics S.A.
Based in Gosselies, Belgium, iTeos, a spin-off of Ludwig Cancer Research (LICR) and de Duve Institute (UCL), is focused on expanding the benefits of immunotherapy for cancer patients. The company is developing a proprietary pipeline targeting A2A, immune checkpoints and non-immunogenic tumors. It has licensed its IDO1 program, now in Phase 1 development, to Pfizer. iTeos' competitive edge is in the combination of expertise in drug discovery and translational tumor immunology. The company uses a unique platform to identify rational combinations of immunotherapies and novel targets. The company is supported in part by the Walloon Region of Belgium and the FEDER (European Fund for Economic and Regional Development). For more information please visit www.iteostherapeutics.com.
Contacts:
Michel Detheux, CEO
iTeos therapeutics
+32 71 919 933
[email protected]
Sarah McCabe
Stern Investor Relations, Inc.
+ 1 212 362-1200
[email protected]
Jonathan Birt, Mathew Neal, Hendrik Thys
Consilium Strategic Communications
+44 203 709 5700
[email protected]
